Nuvei to Acquire Payoneer for $2.75 Billion
A wave of strategic financing and clinical breakthroughs marks the day's corporate updates.
Canopy Growth Corp (CGC) reported fourth-quarter net revenue growth of 68% in international cannabis markets and 27% in Canada medical. The company ended its fiscal year with $131.3 million in net cash following a strategic recapitalization and the acquisition of MTL Cannabis.
In the clinical space, Rhythm Pharmaceuticals, Inc. (RYTM) released Phase 2 data showing that patients with Prader-Willi syndrome treated with setmelanotide achieved clinically meaningful reductions in BMI and fat mass. Spyre Therapeutics, Inc. (SYRE) also reported positive 12-week induction results for SPY002 in ulcerative colitis patients, meeting its primary endpoint with a 10.7-point reduction in the Robart’s Histopathology Index score.
Nuvei has entered a definitive agreement to acquire Payoneer Global Inc. (PAYO) for $7.40 per share in cash, a transaction valued at approximately $2.75 billion. The combined entity expects to process more than $500 billion in annual payment volume. Meanwhile, SharonAI Holdings Inc. (SHAZ) is expanding its Asia-Pacific footprint by deploying 600PB of the VAST AI Operating System to power its sovereign AI cloud infrastructure.
Enhanced Group Inc. (ENHA) secured $50 million in strategic equity financing led by Apeiron Investment Group. Management expects this capital to fund operations until the company reaches operational profitability, targeted for 2027.
Seadrill Ltd (SDRL) intends to offer $600 million in senior unsecured notes due 2034. The company plans to use the proceeds to redeem its outstanding 8.375% senior secured second lien notes due 2030.
Peabody Energy Corp (BTU) has implemented new surety arrangements in the U.S. and Australia to support reclamation obligations. These changes are expected to eliminate a minimum liquidity covenant and reduce total reclamation collateral requirements.